Skip to main contentSkip to navigation
Sirius Investors

Repligen Corporation (RGEN) Investment Research Dashboard

About Repligen Corporation (RGEN) stock analysis

Get live RGEN stock price $131.06, comprehensive Repligen Corporation stock analysis, charts, news, sentiment, sector analysis, and expert forecast. Real-time RGEN stock data and investment insights.

131.06
0.68%Today
Market Cap
7.39B
Volume
1.46M
52W High
175.77
52W Low
100.99

Loading chart data...

Investment Score

TTM (current)
Unavailable

A systematic tri-factor framework (valuation, quality, momentum) using trailing twelve-month fundamentals and current price momentum—aligned with the full investment score dashboard.

Score unavailable for this asset.

0-39

Defensive posture

40-54

Mixed / wait for confirmation

55-69

Constructive setup

70-100

Attractive zone

Total Score

Value

Cheapness vs fundamentals and cash generation

Quality

Durability of profitability and balance sheet

Momentum

Price trend strength and persistence

Professional usage: treat the score as a ranking and risk-filtering tool, then confirm with earnings revision trend, competitive positioning, and valuation relative to peers before capital allocation.

Company Overview

Repligen Corporation specializes in the creation and distribution of advanced bioprocessing technologies and integrated systems. These solutions are vital for various stages of biological drug production, serving clients across North America, Europe,...

Company Information

CEO
Olivier Loeillot
Sector
Healthcare
Industry
Medical - Instruments & Supplies
Employees
2000

Contact Information

Address
Building 1
Country
US

Investment Analysis & Business Insights

Healthcare
Medical - Instruments & Supplies

Investment Highlights

Strong presence in the Healthcare sector with established market position

Growth-oriented company with premium valuation (P/E: 72.8)

Important Investment Considerations

  • All investments carry risk, including potential loss of principal for Repligen Corporation shareholders
  • Market volatility can significantly impact stock price, especially for smaller companies
  • Sector-specific risks in Healthcare may affect company performance
  • Past performance does not guarantee future results for Repligen Corporation
  • Investors should consider how Repligen Corporation fits within their overall portfolio allocation
  • Premium valuation (P/E: 72.8) requires strong growth to justify

Market Cap

7.39B

P/E Ratio (TTM)

72.81

Beta

1.06

Data Sources & Methodology

Financial data on this page is sourced from verified SEC EDGAR filings (10-K, 10-Q, 8-K reports), real-time market data providers, and official company disclosures. All analysis is generated using AI models trained exclusively on reliable financial documents. For detailed information about our data sources and methodology, see our Methodology page.Not investment advice.

About Healthcare Sector

The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.

Healthcare (1D)

72/100 ⭐⭐⭐⭐⭐

Overall
-0.1%
NYSE
-0.1%
NASDAQ
-0.1%
Sector1D1W1MP/EScore
Consumer Defensive+1.3%+3.3%+2.2%29.2
88/100⭐⭐⭐⭐⭐
Financial Services-0.1%+0.9%+2.0%19.3
86/100⭐⭐⭐⭐⭐
Communication Services+0.4%-1.6%+2.0%22.2
74/100⭐⭐⭐⭐⭐
Healthcare-0.1%+0.5%+0.8%23.5
72/100⭐⭐⭐⭐⭐
Basic Materials-0.7%+0.1%-1.3%24.9
60/100⭐⭐⭐⭐
Energy-0.4%-2.0%-2.4%19.4
51/100⭐⭐⭐
Utilities-1.5%-0.5%-4.9%25.4
40/100⭐⭐⭐
Real Estate-1.6%-1.1%-3.5%29.4
36/100⭐⭐
Industrials-0.4%-0.5%-10.7%30.5
19/100
Consumer Cyclical-0.3%-2.3%-6.5%43.1
17/100
Technology-1.9%-4.0%-9.4%41.9
7/100

Sector returns combine NYSE and NASDAQ averages. P/E is the latest blended sector multiple. Sector score ranks each sector vs peers using percentile ranks (not fixed thresholds): 48% 1M + 24% 1W + 8% 1D + 20% P/E (lower P/E ranks higher). Data as of 2026-07-28.